The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Clinical Outcomes of TP53 Mutations in Cancers
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The tumor suppressor gene TP53 is the most frequently mutated gene in human cancers and has been a popular area of research in the field of oncology.”
From p53: from understanding its structure to advances in therapeutic targeting (2026) · cites this paper as [4]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A New Initiative on Precision Medicine
Collins, F. S., & Varmus, H. (2015) · New England Journal of Medicine · doi:10.1056/nejmp1500523 · Cited by 5,202
A microRNA component of the p53 tumour suppressor network
He, L., He, X., Lim, L. P., de Stanchina, E., Xuan, Z., Liang, Y., Xue, W., Zender, L., Magnus, J., Ridzon, D., et al. (2007) · Nature · doi:10.1038/nature05939 · Cited by 2,692
Wild, C. P. (2005) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-05-0456 · Cited by 2,562
The causes and consequences of genetic heterogeneity in cancer evolution
Burrell, R. A., McGranahan, N., Bartek, J., & Swanton, C. (2013) · Nature · doi:10.1038/nature12625 · Cited by 2,262
Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer
Dawson, S.-J., Tsui, D. W. Y., Murtaza, M., Biggs, H., Rueda, O. M., Chin, S.-F., Dunning, M. J., Gale, D., Forshew, T., Mahler-Araujo, B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1213261 · Cited by 2,207
TP53 mutations in human cancers: origins, consequences, and clinical use.
Olivier, M., Hollstein, M., & Hainaut, P. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a001008 · Cited by 2,199 · cited 1×
“Genotoxic exposures to environmental carcinogens and endogenous mutagens promote specific sequence base changes that provide clues to the etiological origins of cancer (Hollstein et al. 1991; Hussain and Harris 1999; Olivier et al. 2010; Schetter and Harris 2012).”
BackgroundFrampton, G. M., Fichtenholtz, A., Otto, G. A., Wang, K., Downing, S. R., He, J., Schnall-Levin, M., White, J., Sanford, E. M., An, P., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2696 · Cited by 2,157 · cited 4×
“Whole genome/ exome Illumina HiSeq 2000 or higher FF (mostly), FFPE 0.5–1 mg Complex 4–6 weeks No aExamples of targeted gene panels are those provided by Foundation Medicine, Personal Genome Diagnostics, and Life Technologies’ AmpliSeq.”
BackgroundMethodInfluentialTransactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis
Chang, T.-C., Wentzel, E. A., Kent, O. A., Ramachandran, K., Mullendore, M., Lee, K. H., Feldmann, G., Yamakuchi, M., Ferlito, M., Lowenstein, C. J., et al. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.05.010 · Cited by 2,010
Definition of a consensus binding site for p53
El-Deiry, W. S., Kern, S. E., Pietenpol, J. A., Kinzler, K. W., & Vogelstein, B. (1992) · Nature Genetics · doi:10.1038/ng0492-45 · Cited by 1,985
Evolution and impact of subclonal mutations in chronic lymphocytic leukemia
Landau, D. A., Carter, S. L., Stojanov, P., McKenna, A., Stevenson, K., Lawrence, M. S., Sougnez, C., Stewart, C., Sivachenko, A., Wang, L., et al. (2013) · Cell · doi:10.1016/j.cell.2013.01.019 · Cited by 1,379
Research works printed but not linked: 118
- 10.1038/nature12477 · DOI · Paper page
- 10.1093/carcin/bgt411 · DOI
- 2012, miR-34—A microRNA replacement therapy is headed to the clinic, Front Genet, 3, 120
- 10.1016/j.cmet.2013.06.019 · DOI · Paper page
- 10.1126/scitranslmed.3007094 · DOI · Paper page
- 2014, TP53 mutants in the tower of babel of cancer progression, Hum Mutat, 35, 689, 10.1002/humu.22514 · DOI
- 10.1016/j.cub.2007.06.068 · DOI · Paper page
- 10.1038/sj.bjc.6603886 · DOI · Paper page
- 10.1186/bcr2811 · DOI
- 2015, Tracking sub-clonal TP53 mutated tumor cells in human metastatic renal cell carcinoma, Oncotarget, 5, 19279
- 10.3390/ijms140919257 · DOI
- 2015, TP53 oncomorphic mutations predict resistance to platinum and taxane-based standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma, Int J Oncol, 46, 607, 10.3892/ijo.2014.2747 · DOI
- 10.1073/pnas.88.22.10124 · DOI · Paper page
- 10.1038/350429a0 · DOI · Paper page
- 10.1158/2159-8290.CD-12-0095 · DOI · Paper page
- 2015, Germline TP53 mutations is common in patients with two early-onset primary malignancies, Clin Genet, 87, 499, 10.1111/cge.12480 · doi:10.1111/cge.12480
- 10.1002/pbc.24316 · DOI
- 10.1073/pnas.1119920109 · DOI · Paper page
- 10.1371/journal.pone.0115383 · DOI · Paper page
- 10.1016/j.cell.2009.06.048 · DOI · Paper page
- 10.1002/hep.26540 · DOI · Paper page
- 10.1158/0008-5472.CAN-07-1585 · DOI · Paper page
- 2015, Appropriateness of using patient-derived xenograft models for pharmacologic evaluation of novel therapies for esophageal/gastro-esophageal junction cancers, PLoS ONE, 10, e0121872, 10.1371/journal.pone.0121872 · doi:10.1371/journal.pone.0121872
- 10.1186/s13058-014-0445-3 · DOI
- 10.1093/nar/gku1075 · DOI · Paper page
- 2012, Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA, Sci Transl Med, 4, 136ra168
- 10.1016/j.cell.2011.12.017 · DOI · Paper page
- 10.1136/jmg.2008.058958 · DOI · Paper page
- 10.1158/1078-0432.CCR-14-0899 · DOI
- 10.1101/cshperspect.a026187 · DOI · Paper page
- 2015, Monitoring gastric cancer progression with circulating tumour DNA, Br J Cancer, 112, 352, 10.1038/bjc.2014.609 · DOI
- 10.1016/j.cell.2011.02.013 · DOI · Paper page
- 10.1016/j.ccr.2007.10.028 · DOI · Paper page
- 10.1097/IGC.0b013e31823ca031 · DOI
- 10.1126/science.1905840 · DOI · Paper page
- 10.1038/ng.2532 · DOI · Paper page
- 1995, Mutations of the K-ras and p53 genes in gastric adenocarcinomas from a high-incidence region around Florence, Italy, Cancer Res, 55, 2665
- 10.1038/ncomms5706 · DOI
- 10.1038/350427a0 · DOI · Paper page
- 10.1101/cshperspect.a026146 · DOI · Paper page
- 10.1016/S1383-5742(99)00028-9 · DOI · Paper page
- 2000, Increased p53 mutation load in noncancerous colon tissue from ulcerative colitis: A cancer-prone chronic inflammatory disease, Cancer Res, 60, 3333
- 10.1073/pnas.220416097 · DOI · Paper page
- 2001, Mutability of p53 hotspot codons to benzo(a)pyrene diol epoxide (BPDE) and the frequency of p53 mutations in nontumorous human lung, Cancer Res, 61, 6350
- 10.1038/ng.2922 · DOI · Paper page
- 10.1073/pnas.0607286103 · DOI · Paper page
- 10.1002/humu.22559 · DOI
- 10.1038/nature12634 · DOI · Paper page
- 10.1073/pnas.1431692100 · DOI · Paper page
- 2012, Molecular therapeutic advances in personalized therapy of melanoma and non-small cell lung cancer, J Pers Med, 2, 35, 10.3390/jpm2020035 · DOI
- 10.1038/nrd4236 · DOI · Paper page
- 2006, Silent mutations in the gene encoding the p53 protein are preferentially located in conserved amino acid positions and splicing enhancers, Mutat Res, 600, 102, 10.1016/j.mrfmmm.2006.03.004 · DOI
- 10.1038/nature12213 · DOI · Paper page
- 10.1016/j.cell.2015.02.045 · DOI · Paper page
- 10.7326/0003-4819-71-4-747 · DOI · Paper page
- 1988, A cancer family syndrome in twenty-four kindreds, Cancer Res, 48, 5358
- 2012, Genome-wide studies of the transcriptional regulation by p53, Biochim Biophys Acta, 1819, 684, 10.1016/j.bbagrm.2012.02.002 · DOI
- 10.1158/1078-0432.CCR-11-0183 · DOI
- 10.1038/onc.2012.299 · DOI
- 2015, The genomic landscape of childhood and adolescent melanoma, J Invest Dermatol, 135, 816, 10.1038/jid.2014.425 · DOI · Paper page
- 2014, TP53 mutation analysis in clinical practice: Lessons from chronic lymphocytic leukemia, Hum Mutat, 35, 663, 10.1002/humu.22508 · DOI
- 10.1038/leu.2014.297 · DOI
- 10.1126/science.1978757 · DOI · Paper page
- 10.1016/j.febslet.2010.10.005 · DOI · Paper page
- 10.1007/s10689-012-9557-z · DOI
- 10.1093/jnci/djv193 · DOI
- 10.1242/dev.02208 · DOI · Paper page
- 10.1093/jnci/djv098 · DOI · Paper page
- 10.1093/jnci/djv101 · DOI · Paper page
- 10.1073/pnas.1017001108 · DOI · Paper page
- 10.1158/1078-0432.CCR-13-2391 · DOI · Paper page
- 10.1097/JTO.0000000000000397 · DOI
- 10.1002/ijc.26077 · DOI
- National Research Council. 2011. Toward precision medicine: Building a knowledge network for biomedical research and a new taxonomy of disease. National Academies Press, Washington, DC.
- 10.1038/342705a0 · DOI · Paper page
- 10.1158/1078-0432.CCR-05-1029 · DOI · Paper page
- 10.1101/cshperspect.a001107 · DOI · Paper page
- 2013, Development and characterization of a bladder cancer xenograft model using patient-derived tumor tissue, Cancer Sci, 104, 631, 10.1111/cas.12123 · doi:10.1111/cas.12123
- 10.1158/1078-0432.CCR-14-0921 · DOI
- 10.1158/1078-0432.CCR-14-2759 · DOI
- 10.1056/NEJMoa073770 · DOI · Paper page
- 10.1126/scitranslmed.3006086 · DOI · Paper page
- 10.1016/j.molcel.2007.05.017 · DOI · Paper page
- 10.1016/j.semcancer.2013.12.006 · DOI
- 10.1101/cshperspect.a001016 · DOI · Paper page
- 10.1182/blood-2013-11-539726 · DOI · Paper page
- 10.1093/annonc/mdu288 · DOI · Paper page
- 10.1182/blood-2011-08-375758 · DOI · Paper page
- 10.1073/pnas.74.12.5463 · DOI · Paper page
- 10.1084/jem.20100797 · DOI
- 10.1073/pnas.1205457109 · DOI
- 10.1038/ng.3252 · DOI · Paper page
- 10.1371/journal.pone.0057799 · DOI
- 10.1016/j.ccr.2012.11.014 · DOI · Paper page
- 10.1073/pnas.1321640111 · DOI · Paper page
- 10.1053/j.gastro.2014.04.036 · DOI
- 10.1158/1078-0432.CCR-11-2260 · DOI · Paper page
- 10.1038/348747a0 · DOI · Paper page
- 10.1182/blood-2014-02-558833 · DOI · Paper page
- 10.1200/JCO.2014.60.1492 · DOI
- 10.1038/onc.2012.586 · DOI
- 10.1038/sj.cdd.4401194 · DOI
- 10.1016/j.cell.2014.01.051 · DOI · Paper page
- 1992, p53 mutations in non-small cell lung cancer in Japan: Association between mutations and smoking, Cancer Res, 52, 734
- 10.4161/cc.6.13.4436 · DOI · Paper page
- 10.1073/pnas.0707351104 · DOI · Paper page
- 10.1158/2159-8290.CD-14-0622 · DOI · Paper page
- 2014, Routine use of the Ion Torrent AmpliSeq Cancer Hotspot Panel for identification of clinically actionable somatic mutations, Clin Chem Lab Med, 52, 707
- 10.1016/S1470-2045(11)70119-X · DOI · Paper page
- 10.1016/j.jhep.2011.03.018 · DOI
- 10.1371/journal.pone.0077065 · DOI
- 10.1038/ng.3013 · DOI · Paper page
- 10.1126/science.1659741 · DOI · Paper page
- 10.1038/nrc2584 · DOI · Paper page
- 10.1053/j.gastro.2010.11.034 · DOI
- 2009, Identification and characterization of a novel germline p53 mutation in a patient with glioblastoma and colon cancer, Int J Cancer, 125, 973, 10.1002/ijc.24432 · DOI
- 2015, Germline TP53 mutations in patients with early-onset colorectal cancer in the Colon Cancer Family Registry, JAMA Oncol, 1, 212
- 10.1200/JCO.2009.27.8762 · DOI · Paper page
Cited by
Mutant p53 cancers reprogram macrophages to tumor supporting macrophages via exosomal miR-1246
Cooks, T., Pateras, I. S., Jenkins, L. M., Patel, K. M., Robles, A. I., Morris, J., Forshew, T., Appella, E., Gorgoulis, V. G., & Harris, C. C. (2018) · Nature Communications · doi:10.1038/s41467-018-03224-w · Cited by 482
Self-citationDrugs Targeting p53 Mutations with FDA Approval and in Clinical Trials
Nishikawa, S., & Iwakuma, T. (2023) · Cancers · doi:10.3390/cancers15020429 · Cited by 115
Long, J., Jia, M.-Y., Fang, W.-Y., Chen, X.-J., Mu, L.-L., Wang, Z.-Y., Shen, Y., Xiang, R.-F., Wang, L.-N., Wang, L., et al. (2020) · Blood · doi:10.1182/blood.2019003538 · Cited by 84
p53: from understanding its structure to advances in therapeutic targeting
Wang, W., Liu, X., Liu, H., Abolhassani, H., Yan, H., Zhang, H., & Wang, X. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02549-5 · Cited by 30
Metadata
- Authors
- Robles, A. I., Jen, J., & Harris, C. C.
- Venue
- Cold Spring Harbor Perspectives in Medicine
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2016-07-22
- Volume
- 6
- Issue
- 9
- Pages
- a026294
- ISSN
- 2157-1422
- Cited by
- 78
- References
- 19
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical Outcomes of TP53 Mutations in Cancers. https://app.cochat.ai/papers/10.1101/cshperspect.a026294
- The paper
- Robles, A. I., Jen, J., & Harris, C. C. (2016). Clinical Outcomes of TP53 Mutations in Cancers. Cold Spring Harbor Perspectives in Medicine. https://doi.org/10.1101/cshperspect.a026294
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.